img

Global Targeted Radionuclide Drug Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Targeted Radionuclide Drug Market Research Report 2024

According to MRAResearch’s new survey, global Targeted Radionuclide Drug market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Targeted Radionuclide Drug market research.
Key companies engaged in the Targeted Radionuclide Drug industry include POINT Biopharma, Telix, ITM AG, Bayer AG, Novartis, Lantheus, Curium Pharma, Fusion Pharmaceuticals and RadioMedix, Inc., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Targeted Radionuclide Drug were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Targeted Radionuclide Drug market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Targeted Radionuclide Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


POINT Biopharma
Telix
ITM AG
Bayer AG
Novartis
Lantheus
Curium Pharma
Fusion Pharmaceuticals
RadioMedix, Inc.
Convergent Therapeutics
IONETIX
Clarity Pharmaceuticals
RayzeBio, Inc
AmbioPharm
Bracco Imaging
Navidea
China Isotope & Radiation Corporation
Yantai Dongcheng
Grand Pharma
Hengrui Medicine
Yunnan Baiyao Group
SmartNuclide Biopharma
Sinotau
Hexin Pharmaceutical
Segment by Type
Medicine
Inhibitor

Segment by Application


Tumors
Thyroid
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Targeted Radionuclide Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Radionuclide Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Medicine
1.2.3 Inhibitor
1.3 Market by Application
1.3.1 Global Targeted Radionuclide Drug Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Tumors
1.3.3 Thyroid
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Targeted Radionuclide Drug Market Perspective (2018-2033)
2.2 Targeted Radionuclide Drug Growth Trends by Region
2.2.1 Global Targeted Radionuclide Drug Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Targeted Radionuclide Drug Historic Market Size by Region (2018-2023)
2.2.3 Targeted Radionuclide Drug Forecasted Market Size by Region (2024-2033)
2.3 Targeted Radionuclide Drug Market Dynamics
2.3.1 Targeted Radionuclide Drug Industry Trends
2.3.2 Targeted Radionuclide Drug Market Drivers
2.3.3 Targeted Radionuclide Drug Market Challenges
2.3.4 Targeted Radionuclide Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted Radionuclide Drug Players by Revenue
3.1.1 Global Top Targeted Radionuclide Drug Players by Revenue (2018-2023)
3.1.2 Global Targeted Radionuclide Drug Revenue Market Share by Players (2018-2023)
3.2 Global Targeted Radionuclide Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Targeted Radionuclide Drug Revenue
3.4 Global Targeted Radionuclide Drug Market Concentration Ratio
3.4.1 Global Targeted Radionuclide Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Radionuclide Drug Revenue in 2022
3.5 Targeted Radionuclide Drug Key Players Head office and Area Served
3.6 Key Players Targeted Radionuclide Drug Product Solution and Service
3.7 Date of Enter into Targeted Radionuclide Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Radionuclide Drug Breakdown Data by Type
4.1 Global Targeted Radionuclide Drug Historic Market Size by Type (2018-2023)
4.2 Global Targeted Radionuclide Drug Forecasted Market Size by Type (2024-2033)
5 Targeted Radionuclide Drug Breakdown Data by Application
5.1 Global Targeted Radionuclide Drug Historic Market Size by Application (2018-2023)
5.2 Global Targeted Radionuclide Drug Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Targeted Radionuclide Drug Market Size (2018-2033)
6.2 North America Targeted Radionuclide Drug Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Targeted Radionuclide Drug Market Size by Country (2018-2023)
6.4 North America Targeted Radionuclide Drug Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Targeted Radionuclide Drug Market Size (2018-2033)
7.2 Europe Targeted Radionuclide Drug Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Targeted Radionuclide Drug Market Size by Country (2018-2023)
7.4 Europe Targeted Radionuclide Drug Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Targeted Radionuclide Drug Market Size (2018-2033)
8.2 Asia-Pacific Targeted Radionuclide Drug Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Targeted Radionuclide Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Targeted Radionuclide Drug Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Targeted Radionuclide Drug Market Size (2018-2033)
9.2 Latin America Targeted Radionuclide Drug Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Targeted Radionuclide Drug Market Size by Country (2018-2023)
9.4 Latin America Targeted Radionuclide Drug Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted Radionuclide Drug Market Size (2018-2033)
10.2 Middle East & Africa Targeted Radionuclide Drug Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Targeted Radionuclide Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Targeted Radionuclide Drug Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 POINT Biopharma
11.1.1 POINT Biopharma Company Detail
11.1.2 POINT Biopharma Business Overview
11.1.3 POINT Biopharma Targeted Radionuclide Drug Introduction
11.1.4 POINT Biopharma Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.1.5 POINT Biopharma Recent Development
11.2 Telix
11.2.1 Telix Company Detail
11.2.2 Telix Business Overview
11.2.3 Telix Targeted Radionuclide Drug Introduction
11.2.4 Telix Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.2.5 Telix Recent Development
11.3 ITM AG
11.3.1 ITM AG Company Detail
11.3.2 ITM AG Business Overview
11.3.3 ITM AG Targeted Radionuclide Drug Introduction
11.3.4 ITM AG Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.3.5 ITM AG Recent Development
11.4 Bayer AG
11.4.1 Bayer AG Company Detail
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Targeted Radionuclide Drug Introduction
11.4.4 Bayer AG Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.4.5 Bayer AG Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Targeted Radionuclide Drug Introduction
11.5.4 Novartis Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.5.5 Novartis Recent Development
11.6 Lantheus
11.6.1 Lantheus Company Detail
11.6.2 Lantheus Business Overview
11.6.3 Lantheus Targeted Radionuclide Drug Introduction
11.6.4 Lantheus Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.6.5 Lantheus Recent Development
11.7 Curium Pharma
11.7.1 Curium Pharma Company Detail
11.7.2 Curium Pharma Business Overview
11.7.3 Curium Pharma Targeted Radionuclide Drug Introduction
11.7.4 Curium Pharma Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.7.5 Curium Pharma Recent Development
11.8 Fusion Pharmaceuticals
11.8.1 Fusion Pharmaceuticals Company Detail
11.8.2 Fusion Pharmaceuticals Business Overview
11.8.3 Fusion Pharmaceuticals Targeted Radionuclide Drug Introduction
11.8.4 Fusion Pharmaceuticals Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.8.5 Fusion Pharmaceuticals Recent Development
11.9 RadioMedix, Inc.
11.9.1 RadioMedix, Inc. Company Detail
11.9.2 RadioMedix, Inc. Business Overview
11.9.3 RadioMedix, Inc. Targeted Radionuclide Drug Introduction
11.9.4 RadioMedix, Inc. Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.9.5 RadioMedix, Inc. Recent Development
11.10 Convergent Therapeutics
11.10.1 Convergent Therapeutics Company Detail
11.10.2 Convergent Therapeutics Business Overview
11.10.3 Convergent Therapeutics Targeted Radionuclide Drug Introduction
11.10.4 Convergent Therapeutics Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.10.5 Convergent Therapeutics Recent Development
11.11 IONETIX
11.11.1 IONETIX Company Detail
11.11.2 IONETIX Business Overview
11.11.3 IONETIX Targeted Radionuclide Drug Introduction
11.11.4 IONETIX Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.11.5 IONETIX Recent Development
11.12 Clarity Pharmaceuticals
11.12.1 Clarity Pharmaceuticals Company Detail
11.12.2 Clarity Pharmaceuticals Business Overview
11.12.3 Clarity Pharmaceuticals Targeted Radionuclide Drug Introduction
11.12.4 Clarity Pharmaceuticals Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.12.5 Clarity Pharmaceuticals Recent Development
11.13 RayzeBio, Inc
11.13.1 RayzeBio, Inc Company Detail
11.13.2 RayzeBio, Inc Business Overview
11.13.3 RayzeBio, Inc Targeted Radionuclide Drug Introduction
11.13.4 RayzeBio, Inc Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.13.5 RayzeBio, Inc Recent Development
11.14 AmbioPharm
11.14.1 AmbioPharm Company Detail
11.14.2 AmbioPharm Business Overview
11.14.3 AmbioPharm Targeted Radionuclide Drug Introduction
11.14.4 AmbioPharm Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.14.5 AmbioPharm Recent Development
11.15 Bracco Imaging
11.15.1 Bracco Imaging Company Detail
11.15.2 Bracco Imaging Business Overview
11.15.3 Bracco Imaging Targeted Radionuclide Drug Introduction
11.15.4 Bracco Imaging Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.15.5 Bracco Imaging Recent Development
11.16 Navidea
11.16.1 Navidea Company Detail
11.16.2 Navidea Business Overview
11.16.3 Navidea Targeted Radionuclide Drug Introduction
11.16.4 Navidea Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.16.5 Navidea Recent Development
11.17 China Isotope & Radiation Corporation
11.17.1 China Isotope & Radiation Corporation Company Detail
11.17.2 China Isotope & Radiation Corporation Business Overview
11.17.3 China Isotope & Radiation Corporation Targeted Radionuclide Drug Introduction
11.17.4 China Isotope & Radiation Corporation Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.17.5 China Isotope & Radiation Corporation Recent Development
11.18 Yantai Dongcheng
11.18.1 Yantai Dongcheng Company Detail
11.18.2 Yantai Dongcheng Business Overview
11.18.3 Yantai Dongcheng Targeted Radionuclide Drug Introduction
11.18.4 Yantai Dongcheng Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.18.5 Yantai Dongcheng Recent Development
11.19 Grand Pharma
11.19.1 Grand Pharma Company Detail
11.19.2 Grand Pharma Business Overview
11.19.3 Grand Pharma Targeted Radionuclide Drug Introduction
11.19.4 Grand Pharma Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.19.5 Grand Pharma Recent Development
11.20 Hengrui Medicine
11.20.1 Hengrui Medicine Company Detail
11.20.2 Hengrui Medicine Business Overview
11.20.3 Hengrui Medicine Targeted Radionuclide Drug Introduction
11.20.4 Hengrui Medicine Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.20.5 Hengrui Medicine Recent Development
11.21 Yunnan Baiyao Group
11.21.1 Yunnan Baiyao Group Company Detail
11.21.2 Yunnan Baiyao Group Business Overview
11.21.3 Yunnan Baiyao Group Targeted Radionuclide Drug Introduction
11.21.4 Yunnan Baiyao Group Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.21.5 Yunnan Baiyao Group Recent Development
11.22 SmartNuclide Biopharma
11.22.1 SmartNuclide Biopharma Company Detail
11.22.2 SmartNuclide Biopharma Business Overview
11.22.3 SmartNuclide Biopharma Targeted Radionuclide Drug Introduction
11.22.4 SmartNuclide Biopharma Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.22.5 SmartNuclide Biopharma Recent Development
11.23 Sinotau
11.23.1 Sinotau Company Detail
11.23.2 Sinotau Business Overview
11.23.3 Sinotau Targeted Radionuclide Drug Introduction
11.23.4 Sinotau Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.23.5 Sinotau Recent Development
11.24 Hexin Pharmaceutical
11.24.1 Hexin Pharmaceutical Company Detail
11.24.2 Hexin Pharmaceutical Business Overview
11.24.3 Hexin Pharmaceutical Targeted Radionuclide Drug Introduction
11.24.4 Hexin Pharmaceutical Revenue in Targeted Radionuclide Drug Business (2018-2023)
11.24.5 Hexin Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Targeted Radionuclide Drug Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Medicine
Table 3. Key Players of Inhibitor
Table 4. Global Targeted Radionuclide Drug Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 5. Global Targeted Radionuclide Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Targeted Radionuclide Drug Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Targeted Radionuclide Drug Market Share by Region (2018-2023)
Table 8. Global Targeted Radionuclide Drug Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Targeted Radionuclide Drug Market Share by Region (2024-2033)
Table 10. Targeted Radionuclide Drug Market Trends
Table 11. Targeted Radionuclide Drug Market Drivers
Table 12. Targeted Radionuclide Drug Market Challenges
Table 13. Targeted Radionuclide Drug Market Restraints
Table 14. Global Targeted Radionuclide Drug Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Targeted Radionuclide Drug Market Share by Players (2018-2023)
Table 16. Global Top Targeted Radionuclide Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Radionuclide Drug as of 2022)
Table 17. Ranking of Global Top Targeted Radionuclide Drug Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Targeted Radionuclide Drug Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Targeted Radionuclide Drug Product Solution and Service
Table 21. Date of Enter into Targeted Radionuclide Drug Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Targeted Radionuclide Drug Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Targeted Radionuclide Drug Revenue Market Share by Type (2018-2023)
Table 25. Global Targeted Radionuclide Drug Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Targeted Radionuclide Drug Revenue Market Share by Type (2024-2033)
Table 27. Global Targeted Radionuclide Drug Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Targeted Radionuclide Drug Revenue Market Share by Application (2018-2023)
Table 29. Global Targeted Radionuclide Drug Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Targeted Radionuclide Drug Revenue Market Share by Application (2024-2033)
Table 31. North America Targeted Radionuclide Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 32. North America Targeted Radionuclide Drug Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Targeted Radionuclide Drug Market Size by Country (2024-2033) & (US$ Million)
Table 34. Europe Targeted Radionuclide Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. Europe Targeted Radionuclide Drug Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Targeted Radionuclide Drug Market Size by Country (2024-2033) & (US$ Million)
Table 37. Asia-Pacific Targeted Radionuclide Drug Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 38. Asia-Pacific Targeted Radionuclide Drug Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Targeted Radionuclide Drug Market Size by Region (2024-2033) & (US$ Million)
Table 40. Latin America Targeted Radionuclide Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 41. Latin America Targeted Radionuclide Drug Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Targeted Radionuclide Drug Market Size by Country (2024-2033) & (US$ Million)
Table 43. Middle East & Africa Targeted Radionuclide Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Middle East & Africa Targeted Radionuclide Drug Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Targeted Radionuclide Drug Market Size by Country (2024-2033) & (US$ Million)
Table 46. POINT Biopharma Company Detail
Table 47. POINT Biopharma Business Overview
Table 48. POINT Biopharma Targeted Radionuclide Drug Product
Table 49. POINT Biopharma Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 50. POINT Biopharma Recent Development
Table 51. Telix Company Detail
Table 52. Telix Business Overview
Table 53. Telix Targeted Radionuclide Drug Product
Table 54. Telix Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 55. Telix Recent Development
Table 56. ITM AG Company Detail
Table 57. ITM AG Business Overview
Table 58. ITM AG Targeted Radionuclide Drug Product
Table 59. ITM AG Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 60. ITM AG Recent Development
Table 61. Bayer AG Company Detail
Table 62. Bayer AG Business Overview
Table 63. Bayer AG Targeted Radionuclide Drug Product
Table 64. Bayer AG Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 65. Bayer AG Recent Development
Table 66. Novartis Company Detail
Table 67. Novartis Business Overview
Table 68. Novartis Targeted Radionuclide Drug Product
Table 69. Novartis Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 70. Novartis Recent Development
Table 71. Lantheus Company Detail
Table 72. Lantheus Business Overview
Table 73. Lantheus Targeted Radionuclide Drug Product
Table 74. Lantheus Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 75. Lantheus Recent Development
Table 76. Curium Pharma Company Detail
Table 77. Curium Pharma Business Overview
Table 78. Curium Pharma Targeted Radionuclide Drug Product
Table 79. Curium Pharma Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 80. Curium Pharma Recent Development
Table 81. Fusion Pharmaceuticals Company Detail
Table 82. Fusion Pharmaceuticals Business Overview
Table 83. Fusion Pharmaceuticals Targeted Radionuclide Drug Product
Table 84. Fusion Pharmaceuticals Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 85. Fusion Pharmaceuticals Recent Development
Table 86. RadioMedix, Inc. Company Detail
Table 87. RadioMedix, Inc. Business Overview
Table 88. RadioMedix, Inc. Targeted Radionuclide Drug Product
Table 89. RadioMedix, Inc. Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 90. RadioMedix, Inc. Recent Development
Table 91. Convergent Therapeutics Company Detail
Table 92. Convergent Therapeutics Business Overview
Table 93. Convergent Therapeutics Targeted Radionuclide Drug Product
Table 94. Convergent Therapeutics Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 95. Convergent Therapeutics Recent Development
Table 96. IONETIX Company Detail
Table 97. IONETIX Business Overview
Table 98. IONETIX Targeted Radionuclide Drug Product
Table 99. IONETIX Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 100. IONETIX Recent Development
Table 101. Clarity Pharmaceuticals Company Detail
Table 102. Clarity Pharmaceuticals Business Overview
Table 103. Clarity Pharmaceuticals Targeted Radionuclide Drug Product
Table 104. Clarity Pharmaceuticals Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 105. Clarity Pharmaceuticals Recent Development
Table 106. RayzeBio, Inc Company Detail
Table 107. RayzeBio, Inc Business Overview
Table 108. RayzeBio, Inc Targeted Radionuclide Drug Product
Table 109. RayzeBio, Inc Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 110. RayzeBio, Inc Recent Development
Table 111. AmbioPharm Company Detail
Table 112. AmbioPharm Business Overview
Table 113. AmbioPharm Targeted Radionuclide Drug Product
Table 114. AmbioPharm Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 115. AmbioPharm Recent Development
Table 116. Bracco Imaging Company Detail
Table 117. Bracco Imaging Business Overview
Table 118. Bracco Imaging Targeted Radionuclide Drug Product
Table 119. Bracco Imaging Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 120. Bracco Imaging Recent Development
Table 121. Navidea Company Detail
Table 122. Navidea Business Overview
Table 123. Navidea Targeted Radionuclide Drug Product
Table 124. Navidea Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 125. Navidea Recent Development
Table 126. China Isotope & Radiation Corporation Company Detail
Table 127. China Isotope & Radiation Corporation Business Overview
Table 128. China Isotope & Radiation Corporation Targeted Radionuclide Drug Product
Table 129. China Isotope & Radiation Corporation Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 130. China Isotope & Radiation Corporation Recent Development
Table 131. Yantai Dongcheng Company Detail
Table 132. Yantai Dongcheng Business Overview
Table 133. Yantai Dongcheng Targeted Radionuclide Drug Product
Table 134. Yantai Dongcheng Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 135. Yantai Dongcheng Recent Development
Table 136. Grand Pharma Company Detail
Table 137. Grand Pharma Business Overview
Table 138. Grand Pharma Targeted Radionuclide Drug Product
Table 139. Grand Pharma Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 140. Grand Pharma Recent Development
Table 141. Hengrui Medicine Company Detail
Table 142. Hengrui Medicine Business Overview
Table 143. Hengrui Medicine Targeted Radionuclide Drug Product
Table 144. Hengrui Medicine Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 145. Hengrui Medicine Recent Development
Table 146. Yunnan Baiyao Group Company Detail
Table 147. Yunnan Baiyao Group Business Overview
Table 148. Yunnan Baiyao Group Targeted Radionuclide Drug Product
Table 149. Yunnan Baiyao Group Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 150. Yunnan Baiyao Group Recent Development
Table 151. SmartNuclide Biopharma Company Detail
Table 152. SmartNuclide Biopharma Business Overview
Table 153. SmartNuclide Biopharma Targeted Radionuclide Drug Product
Table 154. SmartNuclide Biopharma Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 155. SmartNuclide Biopharma Recent Development
Table 156. Sinotau Company Detail
Table 157. Sinotau Business Overview
Table 158. Sinotau Targeted Radionuclide Drug Product
Table 159. Sinotau Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 160. Sinotau Recent Development
Table 161. Hexin Pharmaceutical Company Detail
Table 162. Hexin Pharmaceutical Business Overview
Table 163. Hexin Pharmaceutical Targeted Radionuclide Drug Product
Table 164. Hexin Pharmaceutical Revenue in Targeted Radionuclide Drug Business (2018-2023) & (US$ Million)
Table 165. Hexin Pharmaceutical Recent Development
Table 166. Research Programs/Design for This Report
Table 167. Key Data Information from Secondary Sources
Table 168. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Targeted Radionuclide Drug Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Targeted Radionuclide Drug Market Share by Type: 2022 VS 2033
Figure 3. Medicine Features
Figure 4. Inhibitor Features
Figure 5. Global Targeted Radionuclide Drug Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 6. Global Targeted Radionuclide Drug Market Share by Application: 2022 VS 2033
Figure 7. Tumors Case Studies
Figure 8. Thyroid Case Studies
Figure 9. Others Case Studies
Figure 10. Targeted Radionuclide Drug Report Years Considered
Figure 11. Global Targeted Radionuclide Drug Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 12. Global Targeted Radionuclide Drug Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 13. Global Targeted Radionuclide Drug Market Share by Region: 2022 VS 2033
Figure 14. Global Targeted Radionuclide Drug Market Share by Players in 2022
Figure 15. Global Top Targeted Radionuclide Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Radionuclide Drug as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Targeted Radionuclide Drug Revenue in 2022
Figure 17. North America Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 18. North America Targeted Radionuclide Drug Market Share by Country (2018-2033)
Figure 19. United States Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. Canada Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Europe Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Targeted Radionuclide Drug Market Share by Country (2018-2033)
Figure 23. Germany Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. France Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. U.K. Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Italy Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Russia Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Nordic Countries Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Asia-Pacific Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific Targeted Radionuclide Drug Market Share by Region (2018-2033)
Figure 31. China Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Japan Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. South Korea Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Southeast Asia Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. India Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Australia Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Latin America Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America Targeted Radionuclide Drug Market Share by Country (2018-2033)
Figure 39. Mexico Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Brazil Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Middle East & Africa Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa Targeted Radionuclide Drug Market Share by Country (2018-2033)
Figure 43. Turkey Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Saudi Arabia Targeted Radionuclide Drug Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. POINT Biopharma Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 46. Telix Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 47. ITM AG Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 48. Bayer AG Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 49. Novartis Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 50. Lantheus Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 51. Curium Pharma Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 52. Fusion Pharmaceuticals Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 53. RadioMedix, Inc. Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 54. Convergent Therapeutics Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 55. IONETIX Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 56. Clarity Pharmaceuticals Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 57. RayzeBio, Inc Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 58. AmbioPharm Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 59. Bracco Imaging Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 60. Navidea Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 61. China Isotope & Radiation Corporation Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 62. Yantai Dongcheng Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 63. Grand Pharma Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 64. Hengrui Medicine Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 65. Yunnan Baiyao Group Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 66. SmartNuclide Biopharma Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 67. Sinotau Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 68. Hexin Pharmaceutical Revenue Growth Rate in Targeted Radionuclide Drug Business (2018-2023)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed